This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Huntly BJP, Reid AG, Bench AJ, Campbell LJ, Telford N, Shepherd P, Szer J, Prince HM, Turner P, Grace C, Nacheva EP & Green AR . Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 2001; 98: 1732–1738.
Kolomietz E, Al-Maghrabi J, Brennan S, Karaskova J, Minkin S, Lipton J & Squire JA . Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis. Blood 2001; 97: 3581–3588.
Calabrese G, Stuppia L, Guanciali Franchi P, Peila R, Morizio E, Liberati AM, Spadano A, Di Lorenzo R, Donti E, Antonucci A & Palka G . Complex translocations of the Ph chromosome and Ph negative CML arise from similar mechanisms, as evidenced by FISH analysis. Cancer Genet Cytogenet 1994; 78: 153–159.
Dewald GW, Wyatt WA & Silver RT . Atypical BCR and ABL D-FISH patterns in chronic myeloid leukemia and their possible role in therapy. Leuk Lymphoma 1999; 34: 481–491.
Grand F, Kulkarni S, Chase A, Goldman JM, Gordon M & Cross NCP . Frequent deletion of hSNF5/INI1, a component of the SWI/SNF complex, in chronic myeloid leukemia. Cancer Res 1999; 59: 3870–3874.
Le Gouill S, Talmant P, Milpied N, Daviet A, Ancelot M, Moreau P, Harousseau JL, Bataille R & Avet-Loiseau H . Fluorescence in situ hybridization on peripheral blood specimens is a reliable method to evaluate cytogenetic response in chronic myeloid leukemia. J Clin Oncol 2000; 18: 1533–1538.
Sinclair PB, Nacheva EP, Leversha M, Telford N, Chang J, Reid A, Bench A, Champion K, Huntly B & Green AR . Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood 2000; 95: 738–744.
Herens C, Tassin F, Lemaire V, Beguin Y, Collard E, Lampertz S, Croisiau C, Lecomte M, De Prijk B, Longrée L & Koulischer L . Deletion of the 5′-ABL region: a recurrent anomaly detected by fluorescence in situ hybridization in about 10% of Philadelphia-positive chronic myeloid leukaemia patients. Br J Haematol 2000; 110: 214–216.
Markovic VD, Bouman D, Bayani J, Al-Maghrabi J, Kamel-Reid S & Squire JA . Lack of BCR/ABL reciprocal fusion in variant Philadelphia chromosome translocations: a use of double fusion signal FISH and spectral karyotyping. Leukemia 2000; 14: 1160.
Mohr B, Bornhauser M, Platzbecker U, Freiberg-Richter J, Naumann R, Prange-Krex G, Mohm J, Kroschinsky F, Ehninger G & Thiede C . Problems with interphase fluorescence in situ hybridization in detecting BCR/ABL-positive cells in some patients using a novel technique with extra signals. Cancer Genet Cytogenet 2001; 127: 111–117.
Cohen N, Rozenfeld-Granot G, Hardan I, Brok-Simoni F, Amariglio N, Rechavi G & Trakhtenbrot L . Subgroup of patients with Philadelphia-positive chronic myelogenous leukemia characterized by a deletion of 9q proximal to ABL gene: expression profiling, resistance to interferon therapy, and poor prognosis. Cancer Genet Cytogenet 2001; 128: 114–119.
Gonzalez FA, Anguita E, Mora A, Asenjo S, Lopez I, Polo M & Villegas A . Deletion of BCR region 3′ in chronic myelogenous leukemia. Cancer Genet Cytogenet 2001; 130: 68–74.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Morel, F., Ka, C., Le Bris, MJ. et al. Deletion of the 5′ abl region in Philadelphia chromosome-positive chronic myeloid leukemia. Leukemia 17, 473–474 (2003). https://doi.org/10.1038/sj.leu.2402816
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2402816